Meridian Bioscience Reports Third Quarter 2016 Operating

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance

GENERAL HIGHLIGHTS

CINCINNATI, July 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) today:

  • reported fiscal 2016 third quarter and first nine months net revenues of $50.7 million and $149.1 million, respectively, increases of 5% and 1%, respectively, from the same periods of the prior fiscal year;
  • reported third quarter operating income of $13.7 million, a decrease of 5% from the same period of the prior fiscal year;
  • reported nine months operating income of $42.5 million (including $1.5 million of costs associated with acquisition activity), a decrease of 1% from the same period of the prior fiscal year;
  • reported third quarter net earnings of $8.8 million, or $0.21 per diluted share, decreases of 4% and 5%, respectively, compared to the fiscal 2015 third quarter;
  • reported first nine months net earnings of $28.0 million, or $0.66 per diluted share, on a non-GAAP basis, a 3% increase compared to the same period of fiscal 2015.  On a GAAP basis, earnings were $26.7 million, or $0.63 per diluted share, decreases of 1% and 2%, respectively, compared to the year-to-date fiscal 2015 period.  This non-GAAP basis excludes the effect of costs associated with acquisition activity (see non-GAAP financial measure reconciliation);
  • declared the regular quarterly cash dividend of $0.20 per share for the third quarter of fiscal 2016, (annual indicated rate of $0.80 per share), the same as the regular quarterly rate for fiscal 2015; and
  • updated its fiscal 2016 guidance of per share diluted earnings between $0.86 and $0.90 on a non-GAAP basis on net revenues of $195 million to $200 million, including the Magellan Diagnostics, Inc. acquisition.
 
FINANCIAL HIGHLIGHTS (UNAUDITED) In Thousands, Except per Share Data
 
  Three Months Ended   Nine Months Ended
  June 30,   June 30,
    2016     2015   % Change     2016     2015   % Change
Net Revenues $ 50,665   $ 48,204   5 %   $ 149,084   $ 147,762   1 %
Operating Income   13,741     14,398   -5 %     42,483     42,799   -1 %
Net Earnings   8,754     9,102   -4 %     26,738     27,073   -1 %
Diluted Earnings per Share $ 0.21   $ 0.22   -5 %   $ 0.63   $ 0.64   -2 %
Diluted Earnings per Share                                  
excluding effect of acquisition-                                  
related costs (see non-GAAP                                  
financial measure reconciliation) $ 0.21   $ 0.22   -5 %   $ 0.66   $ 0.64   3 %
                                   
    June 30,                        
  2016     2015                    
Cash and Equivalents $ 45,803   $ 45,975                        
Working Capital   106,672     100,681                        
Long-term Debt   59,250     -                        
Shareholders’ Equity   168,853     163,931                        
Total Assets   254,946     179,316                        
                                   

COMPANY COMMENTS

John A. Kraeutler, Chief Executive Officer and Chairman of the Board said, “Consolidated revenues for the third quarter of fiscal 2016 grew by 5% to $50.7 million versus the prior year. Our Life Science segment, driven largely by strong antigen sales along with robust sales of Zika virus biologicals, combined with our newly acquired Magellan Diagnostics business to contribute almost $6 million in revenue growth.  Our core diagnostic business reported a decline in revenues that detracted from overall results. Modest decreases in C. difficile  testing revenue in this highly competitive market and more recent decreases in our foodborne disease and other non-core product categories contributed to the weaker results.  Our track record of strong operating efficiency continued with gross profit rates increasing by 200 basis points to 65% as compared to the third quarter a year ago.  Major contributors to this improvement included in-house manufacturing of our molecular assays and the elimination of the Medical Device Tax.

During the quarter, we received FDA clearance for a new, moderately complex illumi gene ® test for Mycoplasma pneumoniae .  M. pneumoniae is the primary cause of “walking pneumonia” and is a frequently misdiagnosed respiratory pathogen that can have serious consequences if not treated properly.  The illumi gene molecular product line currently includes a menu of eleven tests making this system a leader in economic value and versatility.  Our Bioline unit continued to expand its reach into the AgriBio industry with new products designed to extract DNA from plant parts such as seeds and leaves.  In addition, the rapidly expanding market for detecting microRNA gained a new tool with the launch of our EPIK Select miRNA product.  And, as mentioned, we continue to supply Zika virus biologicals for use by both diagnostic test manufacturers and researchers. 

With regard to our newest acquisition, Magellan Diagnostics contributed $4.8 million in new revenues, performing better than plan and growing 17% over the prior year. The development of a new point-of-care platform that will complement the pediatric blood lead testing market is largely on schedule. The acquisition is only slightly dilutive to earnings for the quarter after including purchase accounting adjustments, interest expense and professional fees which is better than expected.  The Magellan and Meridian diagnostic teams are collaborating to introduce Meridian products into the physician office market to realize revenue leverage opportunities.

Regarding key personnel matters, I am very pleased to report that Richard (Rick) Eberly, formerly President of Meridian Life Science, has been promoted to the position of President, Chief Commercial Officer.  In his new position, Rick will be responsible for all sales and marketing operations in the core diagnostics and Life Science units as well as the diagnostics research and development efforts.  Rick joined Meridian in 1995 and has been a key player in driving Meridian’s growth in both the diagnostics and life science markets.

Our financial condition is sound and we continue to strive to achieve growth with strong operating leverage.  We continue to seek complementary acquisitions that make maximum use of our core strengths and skills.  Our guidance for fiscal 2016 has been updated to incorporate Magellan, and we expect that our multiple growth opportunities will continue to offset weaknesses in non-focus areas of our business units.”

CASH DIVIDEND MATTERS

The Board of Directors declared the regular quarterly cash dividend of $0.20 per share for the third quarter ended June 30, 2016.  The dividend is of record August 8, 2016 and payable August 18, 2016.  This annual indicated dividend rate of $0.80 per share remains the same as the rate in fiscal 2015.  Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments, including any acquisitions.

FISCAL 2016 GUIDANCE UPDATED

For the fiscal year ending September 30, 2016, management expects net revenues to be in the range of $195 million to $200 million and per share diluted earnings on a non-GAAP basis to be between $0.86 and $0.90, including the acquisition of Magellan Diagnostics, Inc.  The per share estimates assume an increase in average diluted shares outstanding from approximately 42.0 million at fiscal 2015 year end to approximately 42.2 million at fiscal 2016 year end.  The revenue and earnings guidance provided in this press release does not include the impact of any other acquisitions the Company might complete during fiscal 2016.

FINANCIAL CONDITION

The Company’s financial condition is sound.  At June 30, 2016, current assets were $126.9 million compared to current liabilities of $20.2 million, resulting in working capital of $106.7 million and a current ratio of 6.3.  Cash and equivalents were $45.8 million and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility.  The Company’s bank-debt obligations, all of which relate to the acquisition of Magellan, totaled $59.2 million as of June 30, 2016.

INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data)

The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim periods of fiscal 2016 and fiscal 2015.

      Three Months Ended   Nine Months Ended
      June 30,   June 30,
      2016   2015   2016   2015
Net revenues $   50,665     $   48,204     $   149,084     $   147,762  
Cost of sales     17,756         17,873         51,020         55,673  
    Gross profit     32,909         30,331         98,064         92,089  
                           
Operating expenses                      
  Research and development     3,546         3,214         10,056         9,685  
  Selling and marketing     8,085         6,184         21,738         18,745  
  General and administrative     7,537         6,535         22,306         20,860  
  Acquisition-related costs     -         -         1,481         -  
    Total operating expenses     19,168         15,933         55,581         49,290  
                           
Operating income     13,741         14,398         42,483         42,799  
Other income (expense), net     (340 )       (93 )       (591 )       (874 )
  Earnings before income taxes     13,401         14,305         41,892         41,925  
  Income tax provision     4,647         5,203         15,154         14,852  
  Net earnings $   8,754     $   9,102     $   26,738     $   27,073  
                           
Net earnings per basic common share $   0.21     $   0.22     $   0.64     $   0.65  
Basic common shares outstanding     42,076         41,714         42,000         41,647  
                           
Net earnings per diluted common share $   0.21     $   0.22     $   0.63     $   0.64  
Diluted common shares outstanding     42,463         42,093         42,379         41,999  
                                       

The following table sets forth the unaudited segment data for the interim periods in fiscal 2016 and fiscal 2015 (in thousands).

    Three Months Ended   Nine Months Ended
    June 30,   June 30,
    2016   2015   2016   2015
Net revenues                      
  Diagnostics $ 37,523   $   36,049     $   110,178     $   111,297  
  Life Science   13,142       12,155         38,906         36,465  
    $ 50,665   $   48,204     $   149,084     $   147,762  
Operating Income                      
  Diagnostics $ 9,886   $   11,383     $   31,412     $   33,750  
  Life Science   3,696       3,060         11,086         9,145  
  Eliminations   159       (45 )       (15 )       (96 )
    $ 13,741   $   14,398     $   42,483     $   42,799  
                                     

NON-GAAP FINANCIAL MEASURES

In this press release, we have provided information on net earnings, basic earnings per share and diluted earnings per share excluding the effect of costs associated with acquisition activity.  We believe this information is useful to an investor in evaluating our performance because:

  1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impact of non-routine costs related to acquisition activity; and
  2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.

We have provided reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of the acquisition activity noted above, in the tables below for the three and nine month periods ended June 30, 2016 and 2015.

 
THIRD QUARTER AND NINE MONTH YEAR TO DATE GAAP TO NON-GAAP RECONCILIATION TABLES (In Thousands, Except per Share Data)
 
      Three Months   Nine Months
      Ended June 30,   Ended June 30,
      2016   2015   2016   2015
Net Earnings -                      
  U.S. GAAP basis $ 8,754   $ 9,102   $ 26,738   $ 27,073
  Acquisition-related costs   -     -     1,233     -
  Adjusted Earnings $ 8,754   $ 9,102   $ 27,971   $ 27,073
                           
                           
Net Earnings per Basic Common Share -                      
  U.S. GAAP basis $ 0.21   $ 0.22   $ 0.64   $ 0.65
  Acquisition-related costs   -     -     0.03     -
  Adjusted Basic EPS $ 0.21   $ 0.22   $ 0.67   $ 0.65
                           
                           
Net Earnings per Diluted Common Share -                      
  U.S. GAAP basis $ 0.21   $ 0.22   $ 0.63   $ 0.64
  Acquisition-related costs   -     -     0.03     -
  Adjusted Diluted EPS $ 0.21   $ 0.22   $ 0.66   $ 0.64
                           

FORWARD-LOOKING STATEMENTS The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements.  Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context.  All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements.  Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made.  Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance.  Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.  These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products.  While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis.  Meridian relies on proprietary, patented and licensed technologies, and the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results.  Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution.  Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results.  Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products.  The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict.  One of Meridian’s growth strategies is the acquisition of companies and product lines.  There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations.  There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives.  Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations.  Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues.  In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections and blood lead levels. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections; serology, parasitology and fungal disease diagnosis, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com .

 

Contact: 513.271.3700 John A. Kraeutler, Chief Executive Officer

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 0

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 23

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 102

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 41

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Into Guess?, Inc.: Are Fiduciary Duties at Risk?

Updated Category News Views 121

Introduction to the Investigation Recently, a significant issue has arisen concerning Guess?, Inc. (NYSE: GES) and its handling of a pending merger with Authentic Brands Group LLC. This acquisition deal, valued at $16.75 per share, has prompted a legal investigation to determine whether the company's board of directors and top executives may have breached their fiduciary...

Continue Reading
Count Down to Class Action: Important News for GO Investors

Updated Category News Views 281

Important Deadline for Grocery Outlet Holding Corp. Investors As the deadline for the class action lawsuit approaches for Grocery Outlet Holding Corp. (NASDAQ: GO), investors are urged to pay close attention. The law firm Kessler Topaz Meltzer & Check, LLP has announced that investors who purchased or acquired Grocery Outlet securities from November 7, 2023, to May 7,...

Continue Reading
Discover KLIMB Jr.: The Latest in Pet Training Innovation

Updated Category News Views 239

Introducing the KLIMB Jr. by Blue-9 Pet Products Blue-9 Pet Products has made a remarkable stride in pet care with the introduction of the KLIMB Jr., a compact and versatile training platform for dogs and cats. This innovative product serves as a perfect tool for pet owners aiming to enhance their pets’ training and daily enrichment activities. A Tailored Solution for...

Continue Reading
Elsevier, Lancet Awards Highlight Community Health Impact

Updated Category News Views 62

Pioneering Health Awards Make Waves Amidst our swirling universe of breakthroughs and challenges, three research teams just snagged the spotlight. Recognized by the Elsevier Foundation and The Lancet in their first-ever Evidence to Impact Awards. These folks aren't just scribbling in labs—they're rolling up their sleeves and getting those much-needed health solutions...

Continue Reading
k-ID's Kai SDK: Age-Adaptive Design Revolution

Updated Category News Views 139

New Horizons for Developers Today, if you're building an app, you're just as likely to be wrangling with legal regulations as you are writing code. That's where k-ID’s new SDK, Kai, comes into play—it's not just another tool in the shed, it’s the whole toolbox for dealing with age-specific app requirements everywhere. The Changing App Landscape Why does this matter?...

Continue Reading